Cancer Advisor

Comparative evidence review • Experimental oncology • Biomarker hypothesis generation Abstract Background: Antiparasitic drugs have attracted interest as potential repurposed anticancer compounds because several demonstrate cytotoxic, anti-proliferative, metabolic, anti-angiogenic or signaling effects in experimental cancer models. Fenbendazole and mebendazole are benzimidazole anthelmintics with overlapping microtubule-related pharmacology, whereas ivermectin is a macrocyclic lactone with a substantially different molecular profile. A simple “antiparasitic drugs kill cancer cells” framework, however, obscures potentially important genotype and phenotype dependencies. Objective: To construct a comparative cancer biomarker map for fenbendazole (FBZ), mebendazole (MBZ), and ivermectin (IVM), focusing on TP53, MDM2, MDM4/MDMX, KRAS, EGFR, MYC, BRAF, RB1, CDKN2A, GLUT1, HK2, PAK1, YAP1, Wnt/β-catenin, PI3K/Akt/mTOR and related cellular phenotypes. Methods: Experimental, tr...

White Paper · Integrative Oncology · June 2026 ✎ OneDayMD Editorial Team  Last Updated: July 2026   Medically Reviewed by: OneDayMD Editorial Team  DOI-equivalent: onedaymd.com/fenbendazole-cancer-protocol-2026 Abstract Background: Cancer remains the second leading cause of death globally. Advanced-stage disease carries poor prognosis, and a significant proportion of patients either fail conventional therapy or seek adjunctive options. Over the past decade, the repurposed antiparasitic agents fenbendazole, ivermectin, and mebendazole have attracted increasing attention for potential anti-neoplastic activity based on preclinical and emerging clinical data. Objective: To synthesise (1) a systematic case-series compilation of 760+ patient-reported outcomes across 31 cancer subtypes involving antiparasitic repurposed drugs; (2) an evidence-based 7-layer Metabolic Cancer Framework...